Spanish 
English 
Throughout May, June, and July, donations made to Parasites Without Borders (PWB) will be matched by the organization and donated to Foundation for International Medical Relief of Children (FIMRC), for a total gift of up to $10,000. Founded in 2002 by Dr. Vikram D. Bakhru, FIMRC is a U.S.-based nonprofit organization that works to improve access to care through innovative, self-sustaining health programs. FIMRC works alongside communities to improve health from the ground up — including building necessary infrastructure, such as constructing or updating buildings; ensuring communities have access to a healthcare professional; and educating on preventive health.
Learn more at fimrc.org
MicrobeTV Podcast
MicrobeTV is an independent podcast network for people who are interested in the life sciences. Our shows are about viruses, bacteria, parasites, evolution, immunology, and neuroscience.
April 2, 2022
Effect of Early Treatment with Ivermectin among Patients with COVID-19 | Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19A Randomized Clinical Trial | Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19 | Prone positioning of patients with moderate hypoxaemia due to covid-19: multicenter pragmatic randomized trial (COVID-PRONE) | U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals
March 26, 2022
COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022 | Intrinsic Severity of SARS-CoV-2 Omicron BA.2 in Uninfected, Unvaccinated Children: A Population-Based, Case-Control Study on Hospital Complications | SARS-CoV-2 Placentitis and Intraparenchymal Thrombohematomas Among COVID-19 Infections in Pregnancy | De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
March 19, 2022
Children and COVID19: State Level Data Report | Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022 | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 | High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron | Comparison of Seroconversion in Children and Adults With Mild COVID-19
March 12, 2022
SARS-CoV-2 is associated with changes in brain structure | New Onset Dementia Among Survivors of Pneumonia Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Whole genome sequencing reveals host factors underlying critical Covid-19 | Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality | Pfizer Initiated a Phase 2/3 Study of their Novel COVID-19 Oral Treatment in Pediatric Participants | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
March 5, 2022
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID | Development and validation of SCOPE score: a clinical score to predict progression of COVID-19 pneumonia to severe respiratory failure | Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant | Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network
February 26, 2022
Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19, 14 States, July 2021–January 2022 | SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract | Direct Observation of Repeated Infections With Endemic Coronaviruses | Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model | o Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2 | Sanofi and GSK will seek regulatory authorization for their COVID-19 vaccine
- « Anterior
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 53
- Siguiente »
Situation Dashboards
World Health Organization (WHO)
Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
Johns Hopkins University (JHU)
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
COVID-19 in US and Canada
1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
Genomic Epidemiology COVID-19
Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.
